GH Research Announces Phase 2a Results for GH001 in Treating Post-Partum Depression
Written by Emily J. Thompson, Senior Investment Analyst
Updated: Jun 05 2026
0mins
Source: NASDAQ.COM
- Clinical Trial Results: GH Research PLC's Phase 2a trial results for GH001 indicate a significant average reduction of 35.4 points in depression scores among 10 postpartum depression patients over 8 days, demonstrating the drug's efficacy in alleviating postpartum depression symptoms.
- Rapid Relief Effect: Remarkably, 100% of patients achieved remission (MADRS below 10) within two hours of dosing, showcasing GH001's rapid action mechanism and potentially offering a new solution for postpartum depression treatment.
- Improvement in Maternal Functioning: The study also noted an average increase of 34.1 points in maternal functioning assessments, indicating GH001's positive impact on overall maternal well-being, further supporting its clinical application potential.
- Future Research Plans: GH Research stated that these results support further investigation of inhaled mebufotenin in larger randomized controlled trials, highlighting the company's strategic focus on addressing treatment-resistant depression.
Trade with 70% Backtested Accuracy
Stop guessing "Should I Buy GHRS?" and start using high-conviction signals backed by rigorous historical data.
Sign up today to access powerful investing tools and make smarter, data-driven decisions.
Analyst Views on GHRS
Wall Street analysts forecast GHRS stock price to rise
6 Analyst Rating
6 Buy
0 Hold
0 Sell
Strong Buy
Current: 21.700
Low
19.00
Averages
28.60
High
35.00
Current: 21.700
Low
19.00
Averages
28.60
High
35.00
About GHRS
GH Research PLC is a clinical-stage biopharmaceutical company. The Company is focusing on developing its novel and proprietary mebufotenin therapies for the treatment of patients with treatment-resistant depression (TRD). Its portfolio includes GH001, its proprietary inhalable mebufotenin product candidate and GH002, its proprietary intravenous mebufotenin product candidate. GH001 is delivered via a vaporization device produced by a third party, and the Company is developing a proprietary aerosol delivery device which is in clinical investigation in Europe. GH001 completed two Phase 1 clinical trials in healthy volunteers, a Phase 1/2 trial in TRD and two Phase 2a proof-of-concept trials. GH002 Completed a randomized, double-blind, placebo-controlled, dose-ranging clinical pharmacology trial of GH002 in healthy volunteers, and it is developing GH002 within its focus area of psychiatric and neurological disorders.
About the author
Emily J. Thompson
Emily J. Thompson, a Chartered Financial Analyst (CFA) with 12 years in investment research, graduated with honors from the Wharton School. Specializing in industrial and technology stocks, she provides in-depth analysis for Intellectia’s earnings and market brief reports.
GH Research Announces Phase 2a Results for GH001 in Treating Post-Partum Depression
- Clinical Trial Results: GH Research PLC's Phase 2a trial results for GH001 indicate a significant average reduction of 35.4 points in depression scores among 10 postpartum depression patients over 8 days, demonstrating the drug's efficacy in alleviating postpartum depression symptoms.
- Rapid Relief Effect: Remarkably, 100% of patients achieved remission (MADRS below 10) within two hours of dosing, showcasing GH001's rapid action mechanism and potentially offering a new solution for postpartum depression treatment.
- Improvement in Maternal Functioning: The study also noted an average increase of 34.1 points in maternal functioning assessments, indicating GH001's positive impact on overall maternal well-being, further supporting its clinical application potential.
- Future Research Plans: GH Research stated that these results support further investigation of inhaled mebufotenin in larger randomized controlled trials, highlighting the company's strategic focus on addressing treatment-resistant depression.
See More
GH Research Reports Strong Cash Position Amid Q1 Loss
- Financial Performance: GH Research reported a Q1 GAAP EPS of -$0.31, indicating a loss; however, the company maintains a strong cash flow, reflecting ongoing investment in R&D.
- Cash Reserves: As of March 31, 2026, GH Research holds $267.3 million in cash, cash equivalents, and marketable securities, ensuring financial flexibility for future project advancements.
- Capital Raising: The company secured an additional $111.2 million in net cash proceeds from an underwritten offering in April 2026, which will support the advancement of GH001 into Phase 3 clinical trials, enhancing its market competitiveness.
- Market Outlook: With Trump signing legislation to expedite PTSD research, GH Research's prospects in psychedelic treatments, particularly for depression, appear promising, potentially opening new avenues for growth.
See More
GH Research Prices $117.5 Million Stock Offering
- Stock Offering Pricing: GH Research has priced an underwritten offering of 6.53 million ordinary shares at $18 each, aiming for gross proceeds of approximately $117.5 million, which will significantly bolster the company's financial resources for future initiatives.
- Underwriter Participation: The transaction was initiated by Lynx1 Capital Management, with participation from Deep Track Capital and Foresite Capital, while Stifel, Cantor Fitzgerald, and RBC Capital Markets serve as joint book-running managers, reflecting strong market confidence in the company.
- Closing Schedule: The offering is expected to close on April 30, indicating the company's active engagement in capital markets and urgent funding needs, which may influence the advancement of its upcoming projects.
- Market Reaction: Despite a 1% decline in GH Research's shares during premarket trading, the offering is still viewed as a positive step towards enhancing the company's financial position, potentially boosting investor confidence in the long run.
See More
Trump Signs Executive Order to Accelerate Psychedelic Research
- Research Acceleration Policy: President Trump's executive order aims to expedite research on psychedelics like psilocybin and MDMA, although it does not alter drug scheduling, reflecting a focus on a medical-first framework that may pave the way for future cannabis rescheduling.
- Positive Market Reaction: Following the signing of the order, psychedelic developers like AtaiBeckley saw stock prices rise approximately 25%, indicating a positive market response to the policy shift and growing investor confidence in the psychedelic sector.
- Safety Concerns: The inclusion of ibogaine in the order raises safety concerns due to its potential cardiac risks, despite its applications being studied for PTSD and addiction, highlighting significant barriers to commercialization.
- Industry Outlook: While the psychedelic industry lacks a commercial market, the rise of clinical-stage developers suggests that the executive order provides crucial support for the legitimacy of psychedelics, potentially fostering broader acceptance of plant-based alternative medicines in the future.
See More
Trump Signs Executive Order on Psychedelics, Boosting Compass Pathways Stock
- Stock Surge: Compass Pathways' stock surged significantly after President Trump signed an executive order related to psychedelic drugs, reflecting market optimism regarding the company's future, particularly in mental health applications.
- Policy Impact: The executive order may create a more favorable regulatory environment for the research and development of psychedelics, potentially accelerating Compass Pathways' innovation in new therapies and enhancing its competitive position.
- Investor Confidence: Increased attention on psychedelics has drawn more investors to the sector, benefiting Compass Pathways as it is expected to attract more capital to support its R&D projects.
- Industry Outlook: As the therapeutic potential of psychedelics for mental health issues gains recognition, Compass Pathways is poised to lead in this emerging market, driving long-term growth for the company.
See More
Trump Signs Executive Order to Accelerate Psychedelic Drug Reviews
- Market Reaction: Following President Trump's executive order, shares of psychedelic drug developers surged in premarket trading, with Atai Life Sciences up 21%, Definium Therapeutics rising 15%, and Compass Pathways climbing 26%, indicating strong market confidence in the psychedelic sector.
- Executive Order Details: The order directs the FDA to expedite reviews of psychedelic drugs, particularly ibogaine for treating PTSD, depression, and addiction, potentially reducing review times from 6-10 months to just 1-2 months, significantly enhancing the industry's outlook.
- Government Funding Support: Trump announced a $50 million allocation for federal research into ibogaine, providing crucial financial backing for the development of psychedelic drugs and further propelling industry growth.
- Regulatory Risk Mitigation: Analysts noted that the executive order represents a government endorsement of psychedelics, reducing regulatory risks and potentially facilitating legislative efforts to expand access to psychedelic therapies, reflecting bipartisan interest and support in this field.
See More
GH Research Announces Phase 2a Results for GH001 in Treating Post-Partum Depression
- Clinical Trial Results: GH Research PLC's Phase 2a trial results for GH001 indicate a significant average reduction of 35.4 points in depression scores among 10 postpartum depression patients over 8 days, demonstrating the drug's efficacy in alleviating postpartum depression symptoms.
- Rapid Relief Effect: Remarkably, 100% of patients achieved remission (MADRS below 10) within two hours of dosing, showcasing GH001's rapid action mechanism and potentially offering a new solution for postpartum depression treatment.
- Improvement in Maternal Functioning: The study also noted an average increase of 34.1 points in maternal functioning assessments, indicating GH001's positive impact on overall maternal well-being, further supporting its clinical application potential.
- Future Research Plans: GH Research stated that these results support further investigation of inhaled mebufotenin in larger randomized controlled trials, highlighting the company's strategic focus on addressing treatment-resistant depression.
See More
GH Research Reports Strong Cash Position Amid Q1 Loss
- Financial Performance: GH Research reported a Q1 GAAP EPS of -$0.31, indicating a loss; however, the company maintains a strong cash flow, reflecting ongoing investment in R&D.
- Cash Reserves: As of March 31, 2026, GH Research holds $267.3 million in cash, cash equivalents, and marketable securities, ensuring financial flexibility for future project advancements.
- Capital Raising: The company secured an additional $111.2 million in net cash proceeds from an underwritten offering in April 2026, which will support the advancement of GH001 into Phase 3 clinical trials, enhancing its market competitiveness.
- Market Outlook: With Trump signing legislation to expedite PTSD research, GH Research's prospects in psychedelic treatments, particularly for depression, appear promising, potentially opening new avenues for growth.
See More
GH Research Prices $117.5 Million Stock Offering
- Stock Offering Pricing: GH Research has priced an underwritten offering of 6.53 million ordinary shares at $18 each, aiming for gross proceeds of approximately $117.5 million, which will significantly bolster the company's financial resources for future initiatives.
- Underwriter Participation: The transaction was initiated by Lynx1 Capital Management, with participation from Deep Track Capital and Foresite Capital, while Stifel, Cantor Fitzgerald, and RBC Capital Markets serve as joint book-running managers, reflecting strong market confidence in the company.
- Closing Schedule: The offering is expected to close on April 30, indicating the company's active engagement in capital markets and urgent funding needs, which may influence the advancement of its upcoming projects.
- Market Reaction: Despite a 1% decline in GH Research's shares during premarket trading, the offering is still viewed as a positive step towards enhancing the company's financial position, potentially boosting investor confidence in the long run.
See More
Trump Signs Executive Order to Accelerate Psychedelic Research
- Research Acceleration Policy: President Trump's executive order aims to expedite research on psychedelics like psilocybin and MDMA, although it does not alter drug scheduling, reflecting a focus on a medical-first framework that may pave the way for future cannabis rescheduling.
- Positive Market Reaction: Following the signing of the order, psychedelic developers like AtaiBeckley saw stock prices rise approximately 25%, indicating a positive market response to the policy shift and growing investor confidence in the psychedelic sector.
- Safety Concerns: The inclusion of ibogaine in the order raises safety concerns due to its potential cardiac risks, despite its applications being studied for PTSD and addiction, highlighting significant barriers to commercialization.
- Industry Outlook: While the psychedelic industry lacks a commercial market, the rise of clinical-stage developers suggests that the executive order provides crucial support for the legitimacy of psychedelics, potentially fostering broader acceptance of plant-based alternative medicines in the future.
See More
Trump Signs Executive Order on Psychedelics, Boosting Compass Pathways Stock
- Stock Surge: Compass Pathways' stock surged significantly after President Trump signed an executive order related to psychedelic drugs, reflecting market optimism regarding the company's future, particularly in mental health applications.
- Policy Impact: The executive order may create a more favorable regulatory environment for the research and development of psychedelics, potentially accelerating Compass Pathways' innovation in new therapies and enhancing its competitive position.
- Investor Confidence: Increased attention on psychedelics has drawn more investors to the sector, benefiting Compass Pathways as it is expected to attract more capital to support its R&D projects.
- Industry Outlook: As the therapeutic potential of psychedelics for mental health issues gains recognition, Compass Pathways is poised to lead in this emerging market, driving long-term growth for the company.
See More
Trump Signs Executive Order to Accelerate Psychedelic Drug Reviews
- Market Reaction: Following President Trump's executive order, shares of psychedelic drug developers surged in premarket trading, with Atai Life Sciences up 21%, Definium Therapeutics rising 15%, and Compass Pathways climbing 26%, indicating strong market confidence in the psychedelic sector.
- Executive Order Details: The order directs the FDA to expedite reviews of psychedelic drugs, particularly ibogaine for treating PTSD, depression, and addiction, potentially reducing review times from 6-10 months to just 1-2 months, significantly enhancing the industry's outlook.
- Government Funding Support: Trump announced a $50 million allocation for federal research into ibogaine, providing crucial financial backing for the development of psychedelic drugs and further propelling industry growth.
- Regulatory Risk Mitigation: Analysts noted that the executive order represents a government endorsement of psychedelics, reducing regulatory risks and potentially facilitating legislative efforts to expand access to psychedelic therapies, reflecting bipartisan interest and support in this field.
See More
